

April 1, 2009

Mitsubishi Tanabe Pharma Corporation

**Announcement of Signing of License Agreement with EnVivo Pharmaceuticals for EVP-6124**

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka, President: Natsuki Hayama, hereinafter referred to as Mitsubishi Tanabe) has obtained from EnVivo Pharmaceuticals (Massachusetts, USA, CEO: Kees Been, hereinafter referred to as EnVivo) exclusive rights for research, development, marketing and manufacturing in Asian countries including Japan of EVP-6124, which is being developed by EnVivo in the US/European countries.

EVP-6124 is an alpha-7 nicotinic acetylcholine receptor agonist currently in development at EnVivo for use in patients with Alzheimer's disease and with cognitive impairment associated with Schizophrenia. EVP-6124 has already shown positive results in a Phase I clinical trial with Schizophrenia patients and is expected to provide a new therapeutic option for the treatment of Alzheimer's disease in addition to the existing acetylcholinesterase inhibitors.

Under the agreement, Mitsubishi Tanabe has exclusive research, development, marketing and manufacturing rights in Japan, Korea, Taiwan, Indonesia and other Asian countries, and plans to initiate Phase I clinical trials in 2010.

From now on, the two companies are determined to closely collaborate with each other to provide useful therapy earlier for cognition enhancement in patients with Alzheimer's disease and Schizophrenia, making best use of Mitsubishi Tanabe's research and development capability and EnVivo's clinical data.

<About EnVivo>

EnVivo Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system. The company has another Alzheimer's disease program which has a different mechanism of action in its clinical programs other than EVP-6124 and some additional research programs.

Company: EnVivo Pharmaceuticals Inc.  
Address: 480 Arsenal Street, Building #1, Watertown, MA 02472, USA  
Founded: 2001  
Representative: Kees Been, President and Chief Executive Officer  
Employee: about 40 FTE